Role of miR-204 in segmental cardiac effects of phenylephrine and pressure overload

Ravinder Reddy Gaddam1, Veda Sudhir Amalkar2, Veeresh Kumar Sali2

  • 1Department of Internal Medicine, Carver College of Medicine University of Iowa, Iowa City, IA, USA; Abboud Cardiovascular Research Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Insights

This study reveals that microRNA-204 absence exacerbates cardiac dysfunction during phenylephrine-induced cardiotoxicity in mice. These findings highlight miR-204

Area of Science:

  • Cardiology
  • Molecular Biology
  • Echocardiography

Background:

  • Adrenergic agonists and stress can cause cardiotoxicity, mimicking Takotsubo cardiomyopathy (TC).
  • TC involves transient left ventricular systolic dysfunction, but animal models and assessment tools are limited.
  • The role of microRNA-204-5p (miR-204) in TC is unknown, despite its protective function in other cardiomyopathies.

Purpose of the Study:

  • To investigate the impact of miR-204 deficiency on cardiac muscle motion during phenylephrine (PE)-induced and transaortic constriction (TAC)-induced cardiotoxicity.
  • To assess the utility of 2-dimensional speckle-tracking echocardiography (2-STE) in detecting regional wall motion abnormalities in mouse models of cardiac stress.

Main Methods:

  • Wildtype and miR-204 knockout (miR-204-/-) mice were subjected to PE treatment or TAC-induced pressure overload.
  • Cardiac muscle motion in different left ventricular segments was analyzed using 2-dimensional speckle-tracking echocardiography (2-STE).

Main Results:

  • PE treatment increased apical motion and shortened peak motion time in wildtype mice.
  • TAC led to decreased longitudinal and radial motion without altering peak motion time.
  • Compared to wildtype, PE-induced peak motion time was significantly earlier in the anterior base of miR-204-/- mice.

Conclusions:

  • PE and TAC successfully induce regional wall motion abnormalities detectable by 2-STE in mice.
  • miR-204 plays a role in regulating cardiac muscle motion during catecholamine-induced cardiotoxicity.
  • Absence of miR-204 specifically affects cardiac response to PE-induced stress.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
367
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
18
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424